UPDATE: Citi Initiates Coverage on Supernus Pharmaceuticals

According to a research report published this morning, Citi has initiated Supernus Pharmaceuticals

with a Neutral rating and $6 PT. In the report, Citi said, "Our PT is based on a DCF value of $6/share. Our upside & downside Trokendi market share scenarios show a DCF value of >$9 & >$3, respectively. Our High Risk rating reflects the need for additional capital to execute its commercial plans on its extended release (ER) AED's." Supernus Pharmaceuticals closed Friday at $5.98.